Payment overview · 2025
General Payments
$195.81
12 reported records · 6 companies
Healthcare provider profile · identity verified
Brian C Gartrell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COUNCIL BLUFFS, IA · NPI 1225262538
Verified facts
What the public records show
CMS Open Payments records show Brian C Gartrell, M.D. received $195.81 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.22 | 31.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.27 | 25.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.95 | 14.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.85 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.93 | 8.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.59 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $195.81 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.56 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.56 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 922 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 634 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 415 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 106 |
| Losartan Potassium | Losartan Potassium | 353 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 66 |
| Lisinopril | Lisinopril | 276 | 73 |
| Gabapentin | Gabapentin | 262 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 55 |
| Omeprazole | Omeprazole | 248 | 63 |
| Alendronate Sodium | Alendronate Sodium | 234 | 50 |
| Potassium Chloride | Potassium Chloride | 189 | 38 |
| Eliquis | Apixaban | 171 | 39 |
| Montelukast Sodium | Montelukast Sodium | 169 | 39 |
| Trazodone Hcl | Trazodone Hcl | 168 | 46 |
| Meloxicam | Meloxicam | 154 | 35 |
| Furosemide | Furosemide | 152 | 45 |
| Metformin Hcl | Metformin Hcl | 151 | 38 |
| Simvastatin | Simvastatin | 146 | 40 |
| Metformin Hcl Er | Metformin Hcl | 143 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 36 |
| Ezetimibe | Ezetimibe | 122 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 23 |
| Pregabalin | Pregabalin | 104 | 19 |
| Sertraline Hcl | Sertraline Hcl | 100 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 19 |
| Ozempic | Semaglutide | 89 | 12 |
| Jardiance | Empagliflozin | 86 | 15 |
| Mirtazapine | Mirtazapine | 86 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 85 | 19 |
| Prednisone | Prednisone | 84 | 49 |
| Carvedilol | Carvedilol | 82 | 17 |
| Naproxen | Naproxen | 82 | 18 |
| Allopurinol | Allopurinol | 80 | 17 |
| Donepezil Hcl | Donepezil Hcl | 77 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 15 |
| Tramadol Hcl | Tramadol Hcl | 75 | 21 |
| Atenolol | Atenolol | 71 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 18 |
| Irbesartan | Irbesartan | 61 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 13 |
| Spironolactone | Spironolactone | 59 | 18 |
| Finasteride | Finasteride | 54 | 14 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Glimepiride | Glimepiride | 34 | 11 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 28 |
| Amoxicillin | Amoxicillin | 32 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Baclofen | Baclofen | 30 | suppressed |
| Eplerenone | Eplerenone | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Alprazolam | Alprazolam | 27 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 15 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Repatha Syringe | Evolocumab | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Cephalexin | Cephalexin | 22 | 17 |
| Famotidine | Famotidine | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $195.81 · 12 records | ABBVIE INC. | EVENITY, JARDIANCE, Ozempic, PROLIA, QULIPTA, Rybelsus, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error